Metastasis is the deadliest feature of cancer, accounting for greater than 90% of cancer-related mortality.  The clinical manifestation of metastatic lesions is the end result of a treacherous journey that few tumor cells are capable of completing, including local invasion and intravasation, survival in the circulation, homing and extravasation into the parenchyma of distant organs, and finally, adaptation to the new environment and outgrowth of secondary lesions.  Development of successful therapeutic strategies to specifically target metastasis depends on understanding tumor-intrinsic and extrinsic mechanisms that dictate metastatic behaviors, the metastatic niches for the seeding and outgrowth of metastases in different organ sites and the molecular features that render metastatic cancer resistant to current therapies.

The Ludwig Princeton Branch plays a leading role in the study of cancer metastasis, including signaling networks that regulate cellular plasticity during metastasis, stromal niches that regulate organ-tropic metastasis, metabolic adaptation of metastatic cancer cells, as well as the development of novel anti-metastasis therapeutic agents.